An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 1, 2006, Pages 91-99

  Carnell, Dawn M ^a   Smith, Rowena E ^a   Daley, Frances M ^a   Saunders, Michele I ^a   Bentzen, Søren M ^b   Hoskin, Peter J ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Hypoxia; Pimonidazole; Prostate carcinoma; Radioresistance

Indexed keywords

BLOOD VESSELS; CELLS; IMMUNOLOGY; MONOCLONAL ANTIBODIES; PATIENT MONITORING; TUMORS;

HYPOXIA; PIMONIDAZOLE; PROSTATE CARCINOMA; RADIORESISTANCE;

HISTOLOGY;

CD34 ANTIGEN; FORMALDEHYDE; PARAFFIN; PIMONIDAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BINDING; GLEASON SCORE; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; RADIOSENSITIVITY; TISSUE SECTION; TUMOR VASCULARIZATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CELL HYPOXIA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NITROIMIDAZOLES; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 33646007333     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.11.044     Document Type: Article

References (51)

1. American Cancer Society. Detailed guide: Prostate cancer. Accessed at www.cancer.org.
2. Quinn M., and Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90 (2002) 162-173
3. Jani A.B., and Hellman S. Early prostate cancer. Clinical decision-making. Lancet 361 (2003) 1045-1053
4. Crook J., Perry G., Robertson S., et al. Radiotherapy for localized prostate cancer. Assessment of results by systematic biopsy and PSA. Can J Urol 3 (1996) 195-201
5. Kupelian P.A., Elshaikh M., Reddy C.A., et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era. A large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20 (2002) 3376-3385
6. Zagars G.K., von Eschenbach A.C., Ayala A.G., et al. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 68 (1991) 2370-2377
7. Adams G.E. The clinical relevance of tumour hypoxia. Eur J Cancer 26 (1990) 420-421
8. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
9. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
10. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
11. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
12. Nordsmark M., Alsner J., Keller J., et al. Hypoxia in human soft tissue sarcomas. Adverse impact on survival and no association with p53 mutations. Br J Cancer 84 (2001) 1070-1075
13. Nordsmark M., and Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57 (2000) 39-43
14. Movsas B., Chapman J.D., Hanlon A.L., et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer. Preliminary findings. Urology 60 (2002) 634-639
15. Vaupel P., Kelleher D.K., and Thews O. Modulation of tumor oxygenation. Int J Radiat Oncol Biol Phys 42 (1998) 843-848
16. Brown J.M., and Wouters B.G. Comments on hyperbaric oxygen and carbogen/nicotinamide with fractionated radiation. letter; comment. Radiat Res 148 (1997) 526-527
17. Overgaard J., and Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6 (1996) 10-21
18. Overgaard J. Modification of hypoxia-from Gottwald Schwarz to nicotinamide. Have we learned the lesson? (1995), Salzburg, Bologna: Monduzzi Editore 469 Proceedings of the 5th International Meeting on Progress in Radio-Oncology
19. Nahum A.E., Movsas B., Horwitz E.M., et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer. Implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 57 (2003) 391-401
20. Ghafar M.A., Anastasiadis A.G., Chen M.W., et al. Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate 54 (2003) 58-67
21. Movsas B., Chapman J.D., Horwitz E.M., et al. Hypoxic regions exist in human prostate carcinoma. Urology 53 (1999) 11-18
22. Movsas B., Chapman J.D., Greenberg R.E., et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age. An Eppendorf pO(2) study. Cancer 89 (2000) 2018-2024
23. Lyng H., Sundfor K., and Rofstad E.K. Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia. Radiother Oncol 44 (1997) 163-169
24. Nordsmark M., Loncaster J., Chou S., et al. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 49 (2001) 581-586
25. Olive P.L., Banath J.P., and Aquino-Parsons C. Measuring hypoxia in solid tumours-is there a gold standard?. Acta Oncol 40 (2001) 917-923
26. Nordsmark M., Loncaster J., Aquino-Parsons C., et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 67 (2003) 35-44
27. Raleigh J.A., Chou S.C., Arteel G.E., et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 151 (1999) 580-589
28. Arteel G.E., Thurman R.G., and Raleigh J.A. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 253 (1998) 743-750
29. Hockel M., and Vaupel P. Tumor hypoxia. Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93 (2001) 266-276
30. Raleigh J.A., Chou S., Bono E.L., et al. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys 49 (2001) 569-574
31. Tsoli E., Zacharatos P., Dasiou-Plakida D., et al. Growth index is independent of microvessel density in non-small-cell lung carcinomas. Hum Pathol 33 (2002) 812-818
32. Vermeulen P.B., Gasparini G., Fox S.B., et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38 (2002) 1564-1579
33. Zhao D., Ran S., Constantinescu A., et al. Tumor oxygen dynamics. Correlation of in vivo MRI with histological findings. Neoplasia 5 (2003) 308-318
34. Yeh K.A., Biade S., Lanciano R.M., et al. Polarographic needle electrode measurements of oxygen in rat prostate carcinomas. Accuracy and reproducibility. Int J Radiat Oncol Biol Phys 33 (1995) 111-118
35. Parker C., Milosevic M., Toi A., et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 750-757
36. Rasey J.S., Koh W.J., Evans M.L., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole. A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36 (1996) 417-428
37. Kubik-Huch R.A., Hailemariam S., and Hamm B. CT and MRI of the male genital tract. Radiologic-pathologic correlation. Eur Radiol 9 (1999) 16-28
38. Meigs J.B., Mohr B., Barry M.J., et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54 (2001) 935-944
39. Ghafar M.A., Puchner P.J., Anastasiadis A.G., et al. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia?. Curr Urol Rep 3 (2002) 292-296
40. Kirby R.S. The natural history of benign prostatic hyperplasia. What have we learned in the last decade?. Urology 56 (2000) 3-6
41. Borre M., Offersen B.V., Nerstrom B., et al. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78 (1998) 940-944
42. Stefanou D., Batistatou A., Kamina S., et al. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 18 (2004) 155-160
43. Bigler S.A., Deering R.E., and Brawer M.K. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24 (1993) 220-226
44. Offersen B.V., Borre M., and Overgaard J. Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. APMIS 106 (1998) 463-469
45. Fitzgibbons P.L., Page D.L., Weaver D., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124 (2000) 966-978
46. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients. The evidence continues to grow. J Pathol 184 (1998) 119-122
47. West C.M., Cooper R.A., Loncaster J.A., et al. Tumor vascularity. A histological measure of angiogenesis and hypoxia. Cancer Res 61 (2001) 2907-2910
48. Eberhard A., Kahlert S., Goede V., et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors. Implications for antiangiogenic tumor therapies. Cancer Res 60 (2000) 1388-1393
49. Weidner N.C.P., Flax J., Blumenfeld W., et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143 (1993) 401-409
50. Brawer M.K., Deering R.E., Brown M., et al. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73 (1994) 678-687
51. Byar D.P., and Mostofi F.K. Carcinoma of the prostate. Prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer 30 (1972) 5-13